EXTRACELLULAR VESICLES FROM PREVOTELLA
Provided herein are methods and compositions related to Prevotella EVs useful as therapeutic agents.
1 - 181 . (canceled)
182 . A pharmaceutical composition comprising Prevotella bacterial extracellular vesicles (EVs) isolated from Prevotella Strain B 50329 (NRRL accession number B 50329).
183 . The pharmaceutical composition of claim 182 , wherein the composition comprises a pharmaceutically acceptable carrier.
184 . The pharmaceutical composition of claim 182 , wherein the composition comprises at least 1×10 6 Prevotella bacterial extracellular vesicles.
185 . The pharmaceutical composition of claim 182 , wherein at least 90% of the total EV and bacteria particles in the pharmaceutical composition are EVs.
186 . The pharmaceutical composition of claim 182 , wherein the composition further comprises an additional therapeutic.
187 . The pharmaceutical composition of claim 186 , wherein the additional therapeutic is a cancer therapeutic.
188 . The pharmaceutical composition of claim 187 , wherein the cancer therapeutic comprises a chemotherapy agent.
189 . The pharmaceutical composition of claim 187 , wherein the cancer therapeutic comprises an antibiotic.
190 . The pharmaceutical composition of claim 187 , wherein the composition further comprises a prebiotic.
191 . The pharmaceutical composition of claim 186 , wherein the additional therapeutic comprises an immunosuppressive agent, a DMARD, a pain-control drug, a steroid, a non-steroidal anti-inflammatory drug (NSAID), or a cytokine antagonist, and combinations thereof.
192 . A method of treating a disease in a subject comprising administering to the subject the pharmaceutical composition of claim 186 .
193 . The method of claim 192 , wherein the disease is an autoimmune disease, an inflammatory disease, a metabolic disease, or a cancer.
194 . The method of claim 192 , wherein the disease is Nonalcoholic Fatty Liver Disease (NAFLD), Primary Sclerosing Cholangitis (PSC) or Nonalcoholic Steatohepatitis (NASH).
195 . The method of claim 192 , wherein the disease is atopic dermatitis.
196 . The method of claim 192 , wherein the disease is an inflammatory disease.
197 . The method of claim 196 , wherein the inflammatory disease is psoriasis.
198 . The method of claim 192 , wherein the method further comprises administration of an additional therapeutic to the subject.
199 . The method of claim 198 , wherein the disease is cancer and the additional therapeutic is a cancer therapeutic.
200 . The method of claim 199 , wherein the cancer therapeutic comprises a chemotherapy agent.
201 . The method of claim 198 , wherein the disease is an autoimmune disease or an inflammatory disease and the additional therapeutic comprises an immunosuppressive agent, a DMARD, a pain-control drug, a steroid, a non-steroidal anti-inflammatory drug (NSAID), or a cytokine antagonist, and combinations thereof.